



January 9, 2018

Hon. Claire C. Cecchi, U.S.D.J.
United States District Court for the District of New Jersey
Martin Luther King, Jr. Bldg. & U.S. Courthouse
Courtroom MLK 5B
50 Walnut Street
Newark, New Jersey 07101

**Re: Proton-Pump Inhibitor Products Liability Litigation (No. II); 2:17-md-2789
(CCC)(MF) (MDL 2789)**

Dear Judge Cecchi:

Pursuant to this Court's January 8 Order, AstraZeneca ("AZ") submits this letter brief regarding the parties' outstanding discovery disputes concerning search terms and certain of Plaintiffs' requests for production ("RFPs").¹ As set forth more fully below, Plaintiffs have proposed overbroad search terms that would hit on *every* document containing *any* reference to *any* PPI – no matter how irrelevant or tangentially related to this litigation – going back decades. Unless limited, Plaintiffs' proposed terms will return countless documents irrelevant to the litigation and cause AZ's discovery costs to skyrocket. The core issues in this MDL are whether Defendants' product(s) caused Plaintiffs' injuries, and if so, whether Defendants can be held liable for those injuries. Over the past decades, AZ has generated many millions of documents and numerous terabytes of data related to Nexium and Prilosec that have no conceivable relevance to this litigation but will be captured by Plaintiffs' indiscriminate terms – e.g., pricing in more than 100 countries; sales and marketing outside of the US; intellectual property such as patents and trademarks in more than 100 countries; shipping and distribution; product stability; manufacturing specifications; environmental impact; unrelated lawsuits and legal analyses; etc.

The use of such overbroad terms would defeat the very purpose of search terms, which is to identify documents relevant to the litigation and cull out large numbers of irrelevant documents. These types of search terms have been rejected by other courts, and should be rejected here as well given that they would return an immense number of irrelevant documents and impose undue burden and expense on AZ. Similarly, the RFPs discussed below seek information that is neither relevant nor proportional under Rule 26(b)(1).

I. Plaintiffs' Proposed Search Terms Violate Fed. R. Civ. P. 26(b)(1).

A. The Purpose of Search Terms Is to Identify Relevant Documents and Reduce the Burden of Reviewing Documents Unrelated to the Litigation.

Search terms are keywords used "to limit ESI documents to those most likely to be relevant to pending litigation." *Swanson v. ALZA Corp.*, Case No. CV 12-04579, 2013 WL 5538908, at *4 (N.D. Cal. Oct. 7, 2013). Search terms benefit both sides by identifying relevant documents and reducing the burden of reviewing documents unrelated to the parties' claims and defenses (e.g.,

¹ Defendants are conducting separate negotiations with the PSC based on each company's unique data, and where applicable, crafting individualized resolutions on discovery issues including those discussed in this brief. Therefore, as a result, the issues in this brief are before the Court only as to AstraZeneca; the other Defendants have not joined.

e-mails regarding work on other products not at issue, or subject matter not relevant to the litigation).

The standard practice in litigation is for search terms to follow a specific format, known as an A plus B (A+B) approach. Under this approach, A terms are typically words that identify the product(s) at issue. The A terms are then combined with B terms, or modifiers, which are typically words relevant to the litigation – including injury-related terms. For example, an A+B search could consist of “Nexium” AND “kidney.” By running A terms together with B terms, the parties can identify the documents most likely to be relevant to the litigation.

B. Plaintiffs’ Proposed Search Terms Will Return an Immense Number of Irrelevant Documents and Impose Undue Burden and Expense on AZ.

Rule 26(b)(1) limits the scope of discovery to non-privileged, relevant material that is “proportional to the needs of the case,” considering such factors as the importance of the issues at stake and “whether the burden or expense of the proposed discovery outweighs its likely benefit.” Fed. R. Civ. P. 26(b)(1). With this in mind, courts including this one have repeatedly rejected requests for overbroad search terms as disproportionate to the needs of the case.²

Until last week, the parties’ core dispute regarding search terms was the overbreadth of certain modifiers (i.e., B terms) requested by Plaintiffs (*see Exhibit A*). However, during the parties’ December 21 meet and confer, Plaintiffs announced that they were changing their position and would provide an updated list of search terms. On the evening of January 4, fewer than five days before the submission deadline, Plaintiffs all but erased the considerable time and resources invested in negotiating search parameters over the past two months when they sent AZ a new list consisting primarily of stand-alone terms, instead of the previously agreed upon the A+B format (*see Exhibit B*). In addition, Plaintiffs requested a significant number of terms for the first time. Given Plaintiffs’ untimely proposal, AZ has not had adequate time to analyze the terms to assess the resulting volume and burden, but we anticipate a significant increase.

Plaintiffs’ new list runs afoul of standard litigation (and MDL) practice by consisting primarily of stand-alone terms, including product and author names. For example, under Plaintiffs’ proposal, every document and e-mail containing the term “Nexium” will hit on the search terms. Plaintiffs’ proposal appears designed to not only capture *every single* PPI related document created going back decades (including PPIs not manufactured or sold by AZ), but also every

² See, e.g., *In re: Benicar (Olmesartan) Prod. Liab. Litig.*, 2016 WL 5817262, at *7, n.18 (D.N.J. Oct. 4, 2016) (rejecting plaintiffs’ “omnibus requests,” including “general” search terms that would “undoubtedly result in unnecessary and cumulative hits”); *AVM Technologies, LLC v. Intel Corp.*, Case No. 15-00033 (D. Del., May 3, 2016) (rejecting plaintiff’s search term proposal as overbroad and likely to result in numerous irrelevant documents); *see also Rembrandt Diagnostics, LP v. Innovacor, Inc.*, No. 3:16-cv-0698, 2017 U.S. Dist. LEXIS 164015 (S.D. Cal. Oct. 3, 2017) (denying the plaintiff’s motion to compel, concluding that defendant need not conduct an expensive review of its custodians’ extensive emails where the plaintiff’s search terms were unlikely to yield relevant information); *In Re: National Association of Music Merchants, Musical Instruments and Equipment Antitrust Litigation*, MDL No. 2121 (Dec. 19, 2011) (denying plaintiffs’ motion to compel the defendants to run document searches of abbreviations and acronyms identified during discovery, finding that the burden outweighed its likely benefit); *Wilmington Trust v. AEP Generating*, 2016 WL 86093 (S.D. Ohio, March 7, 2016) (holding that the rule of proportionality would be violated if it ordered an additional search which might produce 200,000 documents that would have to be searched manually); *Diesel Power Source v. Crazy Carl’s Turbos*, No. 2:14-CV-826 DN, 2017 WL 57791, at *2 (D. Utah Jan. 5, 2017) (rejecting plaintiff’s five search terms that were related to the claim but were overbroad because they were commonly used in the custodian’s emails, and finding the list a “fishing expedition.”).

document that references any one of more than 65 authors without any limitation (e.g., Warning, Baker, Blank, Chan, Davis, Hung, Johnson, Ray, Simpson, Wall).

The parties have already identified terms most likely to be relevant to Plaintiffs' alleged injuries, and Plaintiffs' attempt to expand discovery with terms that would capture *every* document containing *any* reference to *every* PPI – no matter how irrelevant or tangentially related – is not supported by case law. Suspicion that documents may exist somewhere in the company is not the litmus test for what drives discovery.³ AZ respectfully requests that the Court reject Plaintiffs' attempt to impose overbroad terms. In the alternative, AZ respectfully requests that this Court impose a cost-sharing requirement on Plaintiffs in accordance with Rule 26(b)(2)(C).⁴

C. AZ's Proposed Search Parameters Will Identify the Documents Most Likely to Be Relevant to This Litigation.

AZ will be producing documents from many dozens of sources and has agreed to produce numerous types of documents without applying search terms. In fact, the documents most likely to be relevant to Plaintiffs' claims (consisting of millions of pages) – e.g., regulatory submissions and correspondence with FDA, clinical trial data, draft and final U.S. product labels, etc. – are among those that will be produced without application of search terms.

Moreover, prior to Plaintiffs' sudden change in position, AZ had made significant concessions on search terms. For example, at the outset of negotiations, AZ proposed 880 searches to Plaintiffs (40 A terms and 22 B terms). Pursuant to meet and confer negotiations, AZ agreed to add a substantial number of both A and B terms, resulting in *over 4,620 searches*. These searches (*see Exhibit C*) are more than sufficient to identify potentially relevant documents while ensuring discovery is reasonable and proportionate.

Plaintiffs' contention that AZ's search parameters will deprive them of "highly relevant" documents is without merit. Any "highly relevant" documents will be captured *either* by the search parameters AZ has agreed to *or* from one of the numerous sources that AZ is producing without application of search terms. Other categories of documents that Plaintiffs claim will be lacking are more appropriate for case-specific discovery – e.g., communications with prescribing physicians – and still other search terms proposed by Plaintiffs have *no* relevance to Plaintiffs' claims. For example, Plaintiffs contend that documents regarding "off-label and unbranded promotional activities" are "highly relevant," yet *no* Plaintiff alleges that (s)he was prescribed Nexium or Prilosec for an off-label condition.

Further, Plaintiffs' contention that AZ is unwilling to include marketing and industry search terms is inaccurate. Plaintiffs have proposed vastly overbroad terms relating to marketing, to which AZ objected. For example, Plaintiffs propose "DTC" as a search term (modified by a drug name), which would yield every document even tangentially related to a product's direct to

³ See *Swanson v. ALZA Corporation*, No. CV 12-04579 (N.D. Cal, October 7, 2013) (undertaking a detailed analysis of whether Defendant's suggested search terms would result in undue burden for Plaintiff to search for and review the resulting documents, noting that "a party's suspicion that all responsive documents have not been produced, without more, is generally insufficient to warrant an order compelling production.").

⁴ "On motion or on its own, the court must limit the frequency or extent of discovery otherwise allowed by these rules or by local rule if it determines that...(iii) the proposed discovery is outside the scope permitted by Rule 26(b)(1)." Fed. R. Civ. P. 26(b)(2)(C)(iii). See also *Foreclosure Mgmt. Co. v. Asset Mgmt. Holdings, LLC*, No. 07-2388-DJW, 2008 WL 3822773, at *6-7 (D. Kan. Aug. 13, 2008) (apportioning the cost of document production equally between the parties pursuant to the court's discretion).

consumer (“DTC”) advertising, the vast majority of which will have no relevance to Plaintiffs’ claims. AZ has proposed more focused marketing terms reasonably tailored to identify potentially relevant documents, and AZ is willing to continue meeting and conferring with Plaintiffs about additional terms that will capture potentially relevant documents, without capturing large numbers of irrelevant documents, as with overbroad terms like “DTC.”

D. Plaintiffs’ Attempt to Limit the Application of Search Terms Would Impose Undue Burden and Expense on AZ.

In addition to insisting upon overbroad search terms, Plaintiffs demand that all product specific folder(s) within Custodial Files and Non-Custodial shared workspaces company-wide (e.g. SharePoint, eRooms, shared drives) be reviewed without application of search parameters despite the fact that such folders may not contain *any* documents relevant to this litigation. These types of shared workspaces could relate to any number of product-related subjects that are wholly irrelevant to this litigation, such as patents, distribution and supply chains, foreign marketing and pricing information, etc. The purpose of search terms is to take precisely this type of information – massive amounts of ESI – and identify potentially relevant documents within that universe for review and production. There is no reason to deviate from that standard practice here. AZ should not be required to assume this unnecessary burden and expense.

II. Plaintiffs’ RFPs Violate Fed. R. Civ. P. 26(b)(1).

Plaintiffs served AZ with RFPs totaling 167 specific requests, the items currently in dispute for the Court are limited to three topics:

A. Draft Marketing and Promotional Materials, Physician Education Materials, and Sales Training Materials (RFP Nos. 29-32, 34-35)

Plaintiffs have requested production of draft versions of marketing and other promotional materials related to Prilosec and Nexium. However, draft marketing and promotional materials are not relevant to Plaintiffs’ claims. In these personal injury claims, sales and marketing materials can only be potentially relevant if a physician viewed and relied on them. AstraZeneca did not disseminate any draft marketing or promotional materials to its employees or to anyone outside of the company, including healthcare providers and consumers. Thus, healthcare providers could not have relied on draft materials when prescribing or recommending Nexium or Prilosec to Plaintiffs. Similarly, Plaintiffs could not have relied on draft materials when asking about or deciding to take Nexium or Prilosec. Therefore, draft marketing and promotional materials are irrelevant to Plaintiffs’ failure to warn claims, which turn on the information that AstraZeneca *provided* to healthcare providers and consumers regarding Prilosec and Nexium.

Moreover, Plaintiffs’ request is unduly burdensome as it will require AZ to undertake time intensive privilege review and redaction or logging of protected information of irrelevant documents. Therefore, Plaintiffs’ request is not proportional under Rule 26(b)(1).

B. Information Relating to Prescribing Physicians (RFP Nos. 36-37, 40)

Plaintiffs’ RFP Nos. 36-37 and 40 are vastly overbroad and, to the extent relevant, prematurely seek documents that will be incorporated in the Defendant Fact Sheets. For example, RFP No. 40 seeks “All documents relating or referring to any information, complaints, or questions ever received by Defendants from any physician concerning NEXIUM and PRILOSEC” (emphasis

added). RFP Nos. 36-37 similarly lack any reasonable limitation in scope.⁵ Thus, attempting to collect and produce the information sought by these requests would be unduly burdensome, and the vast majority of documents responsive to these requests are irrelevant to the claims and defenses in this litigation. Plaintiffs' requests necessitate searching nearly 30 databases, some of which may not be amenable to keyword searching, and it would be a time-consuming endeavor to identify entries responsive to Plaintiffs' claims. Even more burdensome would be having to spend *thousands* of hours on collection, review and production of terabytes of data, most of which is wholly irrelevant to Plaintiffs' claims.

Notwithstanding, AstraZeneca is willing to provide information relating to Plaintiffs' prescribing physicians (as opposed to all physicians anywhere) in a manner that comports with the proportionality requirement of Rule 26(b)(1). Accordingly, AstraZeneca will produce the requested information as part of case-specific discovery and is conferring with Plaintiffs' counsel regarding the scope of discovery included in the Defendant Fact Sheet.

C. Communications, Memoranda, and Analyses Sent to or Received from PhRMA Pertaining to PPI Products (RFP Nos. 56-60)

Plaintiffs have requested that AstraZeneca produce all communications with and documents sent to or received from the Pharmaceutical Research and Manufacturers Association of America ("PhRMA"). However, Plaintiffs have been unable to articulate why such documents are likely to be relevant to the specific claims in this litigation. PhRMA is a policy- and advocacy-focused trade association, which does not generally consider product-specific issues. AZ is unaware of any interactions with PhRMA about PPIs and kidney-related diseases, and it would be unduly burdensome to search the files of the numerous AZ employees who have interacted with PhRMA throughout the history of the products to prove the negative.

III. Conclusion

AZ respectfully requests that the Court rule in its favor and deny Plaintiffs' overbroad and indiscriminate terms. Alternatively AZ asks for additional time so it may adequately assess the impact of Plaintiffs' recently proposed search terms and meet and confer to determine which terms remain in dispute. The first rule of federal practice dictates that: "in all civil actions . . . [the Federal Rules of Civil Procedure] should be construed, administered, and employed by the court and the parties to secure the *just, speedy, and inexpensive* determination of every action and proceeding."⁶ Similarly, Rule 26 limits discovery to "matter that is *relevant to any party's claim or defense and proportional to the needs of the case*."⁷ Plaintiffs ask the Court to turn these foundational rules on their heads and order AZ to undertake discovery that is unjustly disproportionate, unduly time consuming, incalculably expensive, and (at best) marginally relevant to their case. AZ respectfully requests that the Court reject Plaintiffs' efforts to unnecessarily expand the proceedings and adopt AZ's more reasonable discovery plan, or alternatively require Plaintiffs to share the costs of their expansive discovery requests.

⁵ RFP No. 36 pertains to information regarding prescribers of PPIs, key opinion leaders (KOLs) or "thought leaders," prescribing data for PPIs, focus groups and voice of the customer reports, and questions or concerns raised by healthcare providers regarding PPIs. RFP No. 37 pertains to documents regarding financial support provided to physicians who lectured or presented regarding PPIs.

⁶ Fed R. Civ P. 1 (emphasis added).

⁷ Fed R. Civ P. 26(b)(1) (emphasis added).

Respectfully submitted,

/s/ Gregory Hindy
Gregory Hindy
Debra M. Perry
MCCARTER & ENGLISH LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07101-0652
T: (973) 622-4444
F: (973) 624-7070
ghindy@mccarter.com
dperry@mccarter.com

/s/ Arthur E. Brown
Arthur E. Brown
Alan E. Rothman
ARNOLD & PORTER
KAYE SCHOLER LLP
250 West 55th Street
New York, NY 10019-9710
T: (212) 836-8000
F: (212) 836-8689
arthur.brown@apks.com
alan.rothman@apks.com

/s/ William Hoffman
William Hoffman
ARNOLD & PORTER
KAYE SCHOLER LLP
601 Massachusetts Ave., NW
Washington, D.C. 2001
T: (202) 942-5000
F: (202) 942-5999
william.hoffman@apks.com

/s/ Amy K. Fisher
Amy K. Fisher
Katherine Althoff
ICE MILLER LLP
One American Square, Suite 2900
Indianapolis, IN 46282
T: (317) 236-2100
F: (317) 592-5443
amy.fisher@icemiller.com
katherine.althoff@icemiller.com

/s/ Makenzie Windfelder
Makenzie Windfelder
James J. Freebery
MCCARTER & ENGLISH LLP
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, DE 19801
T: (302) 984-6300
F: (302) 984-6399
mwindfelder@mccarter.com
jfreebery@mccarter.com
*Attorneys for Defendants AstraZeneca
Pharmaceuticals LP, AstraZeneca LP, and
McKesson Corporation*

<u>ANCHOR TERMS</u>	<u>AND</u>	<u>MODIFIERS</u>
Nexium		"acute tubular necrosis"
Prilosec		AIN
Losec		AKI
esomeprazole		ARF
omeprazole		ATN
H199		CKD
"H 199"		ESRD
H 199/18		glomerular /2 nephritis
H168		glomerulonephritis
"H 168"		glomerular /2 nephritis
H 168/68		glomerulonephritis
H199/18		kidney*
H168/68		nefrit*
199/18		neph*
168/68		njurinsufficiens
PPI		njursjukdom
"proton pump"		njursskada
"protonpumpshämmare"		njursvikt
"purple pill"		Njursvikt
"purple plus"		*renal
Nexiam		renal*
Nexiem		TIN
Nexeum		ATIN
Nexam		Azotemia
Prilosek		dialys*
Prilosik		Dialysis
Prilosic		"_DRESS_"
Prilosik		"Drug reaction with eosinophilia and systemic symptoms syndrome"
Prilesec		eGFR
Prilesek		GFR*
Prilisec		"_GIN_"
Prilisek		interstit*
Prilesic		oliguria
Prilesik		"Potential adverse effects of long term use of PPIs"
Losic		"triad hypersensitivity" w/1 reaction*
Losek		tubule*
esomep*		Tubulitis
esemep*		Tubulointerstitium
esimep*		antigen
esomip*		"blood urea"
omep*		"_BUN_"
omip*		uria*
" eso "		"blood creatine"
" ome "		Lazarus

(NDA or application) /2 (019810 or 19810)		Xie (will need limiter)
(NDA or application) /2 (021153 or 21153)		Aurora (will need limiter)
(NDA or application) /2 (021229 or 21229)		Perazella
(NDA or application) /2 (021689 or 21689)		Reimer (will need limiter)
(NDA or application) /2 (021957 or 21957)		"strategic plan"
(NDA or application) /2 (022056 or 22056)		"marketing plan"
(NDA or application) /2 (022101 or 22101)		"operation plan"
(NDA or application) /2 204655		"operational plan"
(NDA or application) /2 207920		"operations plan"
D9611C00002		ABU
D9611C00003		"annual budget update"
D9617C00001		alkalosis
D9617C00003		BUN
D9617C00011		acidosis
D9618C00001		hypocalc*
D961FC00003		hyponatraemia
D961HC00001		hyperkal*
D961PC00001		uria*
D9914C00001		cholangit*
DC-OMD-0002		"blood alkaline"
I-1003		amylase*
I-1004		sedimentation
I-1101		"antidiuretic hormone"
I-1603		hypoalbum*
I-649		hyperphosph*
I-655		diuretic
SD-NED-0021		rechallenge
SD-NED-0022		hypovolem*
SD-NEE-0003		"European Medicines Agency" OR EMA* OR EMEA*
SH-NEG-0003		"Medicines and Healthcare products regulatory agency" OR MHPRA OR MAHA OR MHRA
SH-NEN-0001		"Health Canada"
SH-NEN-0003		reflux
SH-NEN-0011		GERD
SH-NEN-0013		erosive
SH-NEN-0014		esophagitis
SH-OMG-0004		rebound
SH-QBE-0053		burn
SH-QBE-0054		dose or dosing or "lower dose"

PPIs	gastrointest*
SOPRAN	heartburn
Prevacid	allergic
	off-label
Agreed upon terms	unbranded
Plaintiffs' additional proposed terms	DTC or "direct to consumer"
	OTC or "over the counter"
	KOL
	"thought leader"
	messaging
	branding
	market*
	promot*
	advisory w/2 (board or comm*)
	"opinion leader"
	speaker
	FDA
	OPDP
	PhRMA or "Pharmaceutical Research Manufacturers of America"
	"Scientific Investigations"
	Adcom
	"Adv. Comm**"
	"Core Data Sheet" or "CDS" or "CCDS"
	"Product Insert"
	"Dear Doctor" or "Dear HCP" or "Dear Health Care"
	signal
	CHPA or "Consumer Healthcare Products Association"
	"Public Citizens"
	"detail aid" or "sales aid"
	"obstacle handler" or obstacle response"
	"adverse event" or "serious adverse" or AER or FAER
	"professional education" or "prof ed**"
	pharmacovig* or PV

SEARCH TERMS	MODIFIERS FOR INDIVIDUAL TERMS (IF NEEDED)
DRUG NAMES	
eso	
"proton pump"	
"protonpumpshämmare"	
"purple pill"	
"purple plus"	
Agopton	
Dexal*	
Dexel*	
Dexil*	
dexlanso*	
dexlansop*	
esemep*	
esimep*	
esomep*	
esomip*	
lanso*	
lansop*	
Losec	
Losek	
Losic	
Naprapac	
Nexe*	
Nexi*	
ome	
omep*	
omip*	
panto*	
PPI	
PPIs	
Pravac*	
Prevac*	
Prevoc*	
Prevpac	
Priles*	
Prilos*	
Privac*	
Protium	
Protonix	
Somac	
Takepron	
Tecta	
Zoton	

<u>CLINICAL TRIAL/PROTOCOL/NDA/IND NUMBERS/PROJECT TEAMS</u>	
"300-US"	
"168/68"	
"199/18"	
"301-US"	
"H 168"	
"H 199"	
"IND 069927"	
"IND 106858"	
"IND 30159"	
"IND 41938"	
"IND 41938"	
"IND 44219"	
"IND 44532"	
"IND 47829"	
"IND 49193"	
"IND 58341"	
"IND 60103"	
"IND 63300"	
"IND 72500"	
"PPI Team"	
"Shark Fin"	
(NDA or application) /2 (019810 or 19810)	
(NDA or application) /2 (020406 or 20406)	
(NDA or application) /2 (020876 or 20876)	
(NDA or application) /2 (020877 or 20877)	
(NDA or application) /2 (020878 or 20878)	
(NDA or application) /2 (021153 or 21153)	
(NDA or application) /2 (021229 or 21229)	
(NDA or application) /2 (021281 or 21281)	
(NDA or application) /2 (021331 or 21331)	
(NDA or application) /2 (021428 or 21428)	
(NDA or application) /2 (021507 or 21507)	
(NDA or application) /2 (021566 or 21566)	
(NDA or application) /2 (021689 or 21689)	
(NDA or application) /2 (021957 or 21957)	
(NDA or application) /2 (022056 or 22056)	
(NDA or application) /2 (022101 or 22101)	
(NDA or application) /2 (022287 or 22287)	
(NDA or application) /2 (050743 or 50743)	
(NDA or application) /2 (050757 or 50757)	
(NDA or application) /2 (208056)	
(NDA or application) /2 204655	
(NDA or application) /2 207920	
H168	

H199	
Nobel	
SOPRAN	
MEDICAL/SCIENTIFIC TERMS	
"acute tubular necrosis"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"adverse event" or "serious adverse" or AER or FAER	
"antidiuretic hormone"	
"ATPase inhibitor"	
"blood alkaline"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"blood creatine"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"blood urea"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"Drug reaction with eosinophilia and systemic symptoms syndrome"	

"Potential adverse effects of long term use of PPIs"	
"triad hypersensitivity" w/1 reaction*	
renal	AND (PPI or "Proton Pump" or Nexi or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
acidosis	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
AE	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
AIN	
AKI	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

alkalosis	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
allergic	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
amylase*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
antigen	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
ARF	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

ATIN	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
ATN	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
BUN	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
burn	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
cholangitis*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

CKD	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
dialysis*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
disproportionality	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
diuretic	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
dose or dosing or "lower dose"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

dose-related	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
EB05	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
eGFR	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
erosive	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
esophagitis	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

ESRD	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
gastrointest*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
Azotemia	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
GERD	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
GFR*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

(glomerular /2 nephritis)	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
glomerulonephritis	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
(glomerular /2 nephritis)	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
heartburn	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
hyperkal*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

hyperphosph*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
hypoalbum*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
hypocalc*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
hyponatraemia	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
hypovolem*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

interstit*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
kidney*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
nefrit*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
neph*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
njurinsufficiens	
njursjukdom	
njursskada	
njursvikt	
Njursvikt	

oliguria	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
reflux	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
renal*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"rat study"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"rat studies"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

rats	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
sedimentation	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
signal	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
rebound	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
rechallenge	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

relatedness	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
TIN	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
tubule*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
Tubulitis	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
Tubulointerstitium	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omeprazole* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

uria*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
<u>INDUSTRY/TRADE/MARKETING TERMS</u>	
"Adv. Comm"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"Core Data Sheet" or "CDS" or "CCDS"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"Dear Doctor" or "Dear HCP" or "Dear Health Care"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"detail aid" or "sales aid"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"European Medicines Agency" OR EMA* OR EMEA*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"Health Canada"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"Medicines and Healthcare products regulatory agency" OR MHPRA OR MAHA OR MHRA	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)

"Therapeutic Goods Administration" OR TGA	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"obstacle handler" or obstacle response"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"opinion leader"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"Product Insert"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"professional education" or "prof ed*"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"Public Citizens"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"Scientific Investigations"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin" or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
"thought leader"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
Adcom	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
Adcomm	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
advisory w/2 (board or comm*)	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
branding	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
CHPA or "Consumer Healthcare Products Association"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
DTC or "direct to consumer"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
FDA	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
KOL	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omep* or Nobel or "Shark Fin")
"Larry the Cable Guy"	

market*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
MedWatch	AND (PPI or "Proton Pump" or Nexium or Prilosec or Esomeprazole or Omeprazole or 3001 or "300-US" or "301-US" or H168 or H199 or 19810 or 20406 or 20876 or 20877 or 20878 or 21153 or 21229 or 21281 or 21331 or 21428 or 21507 or 21566 or 21689 or 21957 or 22056 or 22101 or 22287 or 50743 or 50757 or 20856 or 204655 or 207920 or 69927 or 106858 or 30159 or 41938 or 44219 or 44532 or 47829 or 49193 or 58341 or 60103 or 63300 or 72500)
messaging	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
off-label	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
OPDP	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
OTC or "over the counter"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
pharmacovig* or PV	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
PhRMA or "Pharmaceutical Research Manufacturers of America"	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
PI	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
promot*	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
speaker	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
unbranded	AND (PPI or "Proton Pump" or Nexi* or Prilo* or Esome* or Omepr* or Nobel or "Shark Fin")
wildberry	
<u>AUTHORS AND JOURNAL NAMES (FOR ARTICLES CONCERNING PPIs)</u>	
Amiri	
Antoniou	
Arora	
Avinash	
Badov	
Baker	
Berney-Meyer	
Bjorkman	
Blank	
Brewster	
Chan	
Christensen	

Coca	
d'Adamo	
Davis	
Delve	
Doshi	
Eusebi	
"Excerpta Medica"	
Freedberg	
Gatt	
Geevasinga	
Goodsall	
Gronich	
Härmark	
Hung	
Johnson	
Katz	
Kheloufi	
Klassen	
Klatte	
Klepser	
Landray	
Lazarus	
Leonard	
Lieten	
Limaye	
Maes	
Malfertheiner	
Moledina	
Muriithi	
Nast	
Nochaiwong	
Noone	
Peloton	
Peng	
Perazella	
Ray	
Ricketson	
Ruffenach	
Sachs	
Sampathkumar	
Scarpignato	
"Scientific Connexions"	
Sierra	
Simpson	
Stancavish	
Tomlinson	
Torpey	

Toth-Manikowski	
Vaezi	
Wall	
Wallerstedt	
Warning	
Wijarnpreecha	
Wolters	
Wu	
Xie	
Yadlapati	
Yepuri	
"Am J Med" OR "American Journal Medicine"	DATE RANGE (03/01/92 TO 09/01/92)
"Am J Med" OR "American Journal Medicine"	DATE RANGE (08/01/93 TO 02/01/94)
Lancet	DATE RANGE (10/01/92 TO 04/01/93)
"Aust NZ J Med" OR "Australian and New Zealand Journal of Medicine"	DATE RANGE (04/01/94 TO 10/01/94)
"J Am Soc Nephrol" OR "Journal of the American Society of Nephrology"	DATE RANGE (06/01/94 TO 12/01/94)
Lancet	DATE RANGE (05/20/94 TO 02/01/95)
"Clin Nephrol" OR "Clinical Nephrology"	DATE RANGE (05/01/94 TO 11/01/94)
"Med J Aust" OR "Medical Journal of Australia"	DATE RANGE (05/01/96 TO 11/01/96)
"Ren Fail" OR "Renal Failure"	DATE RANGE (10/01/96 TO 04/01/97)
"Nephrol Dial Transplant" OR "Nephrology Dialysis Transplantation"	DATE RANGE (03/01/97 TO 09/01/97)
"J Clin Gastroenterol" OR "Journal of Clinical Gastroenterology"	DATE RANGE (06/01/97 TO 12/01/97)
"Am J Nephrol" OR "American Journal of Nephrology" OR "Journal of Nephrology"	DATE RANGE (12/01/96 TO 05/01/97)
"Postgrad Med J" OR "Postgraduate Medicine Journal"	DATE RANGE (10/01/97 TO 04/01/98)
"Am J Gastroenterol" OR "Journal of Gastroenterology" OR "American Gastroenterology"	DATE RANGE (03/01/99 TO 03/01/00)
"Aust NZ J Med" OR "Australian and New Zealand Journal of Medicine"	DATE RANGE (10/01/98 TO 04/01/99)
"Nephrol Dial Transplant" OR "Nephrology Dialysis Transplantation"	DATE RANGE (01/01/00 TO 07/01/00)
"Neth J Med" OR "Netherlands Journal of Medicine"	DATE RANGE (02/01/00 TO 08/01/00)
Nursing	DATE RANGE (07/01/00 TO 02/01/01)
"Australian Adverse Drug Reaction Bulletin" OR AADR	DATE RANGE (01/01/03 TO 07/01/03)
"N Z Med J" OR "New Zealand Medical Journal"	DATE RANGE (12/01/02 TO 05/01/03)

"Ann Pharmacother" OR "Annals of Pharmacotherapy"	DATE RANGE (10/01/03 TO 04/01/04)
"J Nephrol" OR "Journal of Nephrology" OR "Nephrology Journal"	DATE RANGE (01/01/04 TO 07/01/04)
"Nephrol Dial Transplant" OR "Nephrology Dialysis Transplantation"	DATE RANGE (10/01/03 TO 06/01/04)
Nephrology	DATE RANGE (08/01/04 TO 02/01/05)
"Med J Aust" OR "Medical Journal of Australia"	DATE RANGE (09/01/05 TO 02/01/06)
"Clin Gastroenterol Hepatol" OR "Clinical Gastroenterology"	DATE RANGE (02/01/06 TO 08/01/06)
Nephrology	DATE RANGE (03/01/06 TO 09/01/06)
"Aust Prescrib" OR "Australian Prescriber"	DATE RANGE (03/01/07 TO 09/01/07)
"Kidney Int" OR "Kidney Intl" OR "Kidney International"	DATE RANGE (09/01/07 TO 03/01/08)
"Clin Nephrol" OR "Clinical Nephrology"	DATE RANGE (01/01/07 TO 06/01/07)
"Aliment Pharmacol Ther" OR "Alimentary Pharmacology"	DATE RANGE (03/01/06 TO 09/01/06)
"Br J Clin Pharmacol" OR "British Journal of Pharmacology"	DATE RANGE (04/01/07 TO 10/01/07)
CMAJ OR "Canadian Medical Association"	DATE RANGE (12/01/08 TO 06/01/09)
"Hosp Phys" OR "Hospital Physician"	DATE RANGE (11/01/08 TO 05/01/09)
"Nat Rev Nephrol" OR "Nature Reviews Nephrology"	DATE RANGE (05/01/10 TO 11/01/10)
BMJ	DATE RANGE (06/01/10 TO 12/01/10)
JAGS OR "American Geriatrics Society"	DATE RANGE (09/01/10 TO 03/01/11)
"Pharmacoepidemiol Drug Saf" OR "Pharmacoepidemiology"	DATE RANGE (05/01/12 TO 11/01/12)
CMAJ OR "Canadian Medical Association"	DATE RANGE (10/01/12 TO 04/01/13)
"Indian J Nephrol" OR "Indian Journal of Nephrology"	DATE RANGE (05/01/13 TO 11/01/13)
"BMC Nephrol" OR "Biomed Central Nephrology"	DATE RANGE (04/01/13 TO 10/01/13)
"CMJ Case Report" OR "Ceylon Medical Journal"	DATE RANGE (07/01/14 TO 01/01/15)
"J Nephrol Ther" OR "Journal of Nephrology" OR "Nephrology and Therapeutics"	DATE RANGE (01/01/14 TO 07/01/14)
Nephrology	DATE RANGE (01/01/14 TO 07/01/14)
"Am J Kidney Dis" OR "Journal of Kidney Disease"	DATE RANGE (03/01/14 TO 09/01/14)
"Kidney Int" OR "Kidney Intl" OR "Kidney International"	DATE RANGE (12/01/13 TO 06/01/14)
"CMAJ Open" OR "Canadian Medical Association"	DATE RANGE (01/01/15 TO 07/01/15)
"Marshall Journal of Medicine"	DATE RANGE (10/01/15 TO 04/01/16)

"JAMA Intern Med" OR JAMA OR "Jama Internal Medicine"	DATE RANGE (10/01/15 TO 04/01/16)
"J Clin Pharmacol" OR "Journal of Clinical Pharmacology"	DATE RANGE (09/01/16 TO 02/01/17)
"Medicine (Baltimore)" OR "Medicine Baltimore"	DATE RANGE (01/01/16 TO 07/01/16)
"Circ Res" OR "Circulation Research"	DATE RANGE (02/01/16 TO 08/01/16)
"Int J Basic Clin Pharmacol" OR "Basic & Clinical Pharmacology"	DATE RANGE (04/01/16 TO 10/01/16)
"BMC Nephrol" OR "Biomed Central Nephrology"	DATE RANGE (08/01/16 TO 02/01/17)
"J Am Soc Nephrol" OR "Journal of the American Society of Nephrology"	DATE RANGE (12/01/15 TO 06/01/16)
"J Nephrol" OR "Journal of Nephrology" OR "Nephrology Journal"	DATE RANGE (01/01/16 TO 07/01/16)
"BMC Med" OR "Biomed Central Medicine"	DATE RANGE (08/01/16 TO 02/01/17)
"Pharmacoepidemiol Drug Saf" OR "Pharmacoepidemiology"	DATE RANGE (07/01/16 TO 01/01/18)
"J Gastroenterol Hepatol" OR "Journal of Gastroenterology"	DATE RANGE (10/01/16 TO 04/01/17)
"Nephrol Dial Transplant" OR "Nephrology Dialysis Transplantation"	DATE RANGE (12/01/16 TO 06/01/17)
"Adv Chronic Kidney" OR "Advances in Chronic Kidney Disease" OR "National Kidney Foundation"	DATE RANGE (12/01/16 TO 06/01/17)
Gastroenterology OR "American Gastroenterological Association"	DATE RANGE (12/01/16 TO 08/01/17)
"Kidney International Reports" OR "Kidney Intl" OR "Kidney International"	DATE RANGE (09/01/16 TO 04/01/17)
"J CLINICAL & DIAGNOSTIC RESEARCH" OR "Clinical and Diagnostic Research"	DATE RANGE (01/01/17 TO 07/01/17)
"J Renal Endocrinology" OR "Journal of Renal Endocrinology"	DATE RANGE (01/01/17 TO 07/01/17)
"J Clinical Endocrinology & Metabolism" OR "Journal of Clinical Endocrinology"	DATE RANGE (03/01/17 TO 10/01/17)
"Therapeutic Advances in Drug Safety"	DATE RANGE (06/01/17 TO 12/01/17)
"BMJ Open"	DATE RANGE (12/01/16 TO 06/01/17)
"J Allergy & Clinical Immunology" OR "Journal of Allergy"	DATE RANGE (03/01/17 TO 10/01/17)
Gastroenterology OR "American Gastroenterological Association"	DATE RANGE (06/01/17 TO 12/01/17)
"Digestive Diseases and Sciences"	DATE RANGE (05/01/17 TO 01/01/18)
"Gastroenterology & Hepatology"	DATE RANGE (06/01/17 TO 12/01/17)
"European Geriatric Medicine" OR "European Geriatric"	DATE RANGE (08/01/17 TO 02/01/18)
"Family Practice"	DATE RANGE (07/01/17 TO 01/01/18)
Therapie	DATE RANGE (05/01/17 TO 01/01/18)

"Clin Epidemiol Global Health" OR "Clinical Epidemiology" OR "Epidemiology and Global Health"	DATE RANGE (09/01/17 TO CURRENT)
---	----------------------------------

<u>ANCHOR TERMS</u>	<u>AND</u>	<u>MODIFIERS</u>
Nexium		"acute tubular necrosis"
Prilosec		AIN
Losec		AKI
esomeprazole		ARF
omeprazole		ATN
H199		CKD
"H 199"		ESRD
H 199/18		glomerular /2 nephritis
H168		glomerulonephritis
"H 168"		glomerular /2 nephritis
H 168/68		glomerulonephritis
H199/18		kidney*
H168/68		nefrit*
199/18		neph*
168/68		njurinsufficiens
PPI		njursjukdom
"proton pump"		njursskada
"protonpumpshämmare"		njursvikt
"purple pill"		Njursvikt
"purple plus"		*renal
Nexiam		renal*
Nexiem		TIN
Nexeum		ATIN
Nexam		Azotemia
Prilosek		dialys*
Prilosik		Dialysis
Priloscic		"_DRESS_"
Prilosik		"Drug reaction with eosinophilia and systemic symptoms syndrome"
Prilesec		eGFR
Prilesek		GFR*
Prilisec		"_GIN_"
Prilisek		interstit*
Prilesic		oliguria
Prilesik		"Potential adverse effects of long term use of PPIs"
Losic		"triad hypersensitivity" w/1 reaction*
Losek		tubule*
esomep*		Tubulitis
esemep*		Tubulointerstitium
esimep*		antigen
esomip*		"blood urea"
omep*		"_BUN_"
omip*		uria*
" eso "		"blood creatine"
" ome "		Lazarus

(NDA or application) /2 (019810 or 19810)		Xie (will need limiter)
(NDA or application) /2 (021153 or 21153)		Aurora (will need limiter)
(NDA or application) /2 (021229 or 21229)		Perazella
(NDA or application) /2 (021689 or 21689)		Reimer (will need limiter)
(NDA or application) /2 (021957 or 21957)		"strategic plan"
(NDA or application) /2 (022056 or 22056)		"marketing plan"
(NDA or application) /2 (022101 or 22101)		"operation plan"
(NDA or application) /2 204655		"operational plan"
(NDA or application) /2 207920		"operations plan
D9611C00002		ABU
D9611C00003		"annual budget update"
D9617C00001		
D9617C00003		
D9617C00011		
D9618C00001		
D961FC00003		
D961HC00001		
D961PC00001		
D9914C00001		
DC-OMD-0002		
I-1003		
I-1004		
I-1101		
I-1603		
I-649		
I-655		
SD-NED-0021		
SD-NED-0022		
SD-NEE-0003		
SH-NEG-0003		
SH-NEN-0001		
SH-NEN-0003		
SH-NEN-0011		
SH-NEN-0013		
SH-NEN-0014		
SH-OMG-0004		
SH-QBE-0053		
SH-QBE-0054		
PPIs		
SOPRAN		